High specific activity is not optimal: 18F-fluoroestradio positron emission tomography-computed tomography results in a breast cancer xenograft

被引:3
作者
Yang, Zhongyi [1 ,2 ,3 ,4 ]
Yuan, Huiyu [1 ,2 ,3 ,4 ]
Xu, Xiaoping [1 ,2 ,3 ,4 ]
Gu, Bingxin [1 ,2 ,3 ,4 ]
Wang, Mingwei [1 ,2 ,3 ,4 ]
Zhang, Jianping [1 ,2 ,3 ,4 ]
Zhang, Yongping [1 ,2 ,3 ,4 ]
Zhang, Yingjian [1 ,2 ,3 ,4 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Nucl Med, 270 Dongan Rd, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Fudan Univ, Ctr Biomed Imaging, Shanghai, Peoples R China
[4] Shanghai Engn Res Ctr Mol Imaging Probes, Shanghai, Peoples R China
关键词
breast cancer; F-18-FES micro-PET; CT; nude mouse; specific activity; TARGET TISSUES; ESTROGEN; PET; HETEROGENEITY; EXPRESSION;
D O I
10.1002/jlcr.3467
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The purpose of the preliminary study was to investigate whether high specific activity (SA) of F-18-fluoroestradiol was optimal in breast cancer diagnosis. Imaging at variable SA was conducted in a ZR-75-1 xenograft model of estrogen-receptor positive human breast cancer in 6 mice. The region of interest was manually drawn, and the percent of injected dose per gram of the tumor and muscle in the regions of interest were recorded. Tumor-to-muscle ratio (T/M) was calculated and compared in each group with different SAs. In addition, the correlation between blood estradiol and sex hormone-binding globulin and the value of T/M were also analyzed. The value of T/M increased initially with the rise of SA and it reached the peak at SA of 1.6Ci/mol. After that, the value fell down sharply and remained stable from SA of 3.1Ci/mol. The value of T/M was highest at SA of 1.6Ci/mol (P<.001). Additionally, the blood levels of estradiol and sex hormone-binding globulin showed no correlation with the value of T/M (P>.05). High SA of F-18-fluoroestradiol leads to low T/M results in breast cancer xenograft models. We should control SA in a reasonable range to obtain high-quality images.
引用
收藏
页码:576 / 581
页数:6
相关论文
共 32 条
[1]  
[Anonymous], ASIAN PAC J CANC PRE
[2]   BREAST CANCERS - ESTROGEN AND PROGESTERONE-RECEPTOR STATUS AS A PREDICTOR OF INVITRO CHEMOTHERAPEUTIC RESPONSE [J].
BERTELSEN, CA ;
GIULIANO, AE ;
KERN, DH ;
MANN, BD ;
ROE, DJ ;
MORTON, DL .
JOURNAL OF SURGICAL RESEARCH, 1984, 37 (04) :257-263
[3]   SURVIVAL FROM 1ST RECURRENCE - RELATIVE IMPORTANCE OF PROGNOSTIC FACTORS IN 1,015 BREAST-CANCER PATIENTS [J].
CLARK, GM ;
SLEDGE, GW ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :55-61
[4]  
DEHDASHTI F, 1995, J NUCL MED, V36, P1766
[5]   Evolution of knowledge related to breast cancer heterogeneity: A 25-year retrospective [J].
Fisher, Bernard ;
Redmond, Carol K. ;
Fisher, Edwin R. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2068-2071
[6]   Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer [J].
Fowler, Amy M. ;
Chan, Szeman Ruby ;
Sharp, Terry L. ;
Fettig, Nicole M. ;
Zhou, Dong ;
Dence, Carmen S. ;
Carlson, Kathryn E. ;
Jeyakumar, M. ;
Katzenellenbogen, John A. ;
Schreiber, Robert D. ;
Welch, Michael J. .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (07) :1119-1126
[7]   Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer [J].
Gemignani, Mary L. ;
Patil, Sujata ;
Seshan, Venkatraman E. ;
Sampson, Michelle ;
Humm, John L. ;
Lewis, Jason S. ;
Brogi, Edi ;
Larson, Steven M. ;
Morrow, Monica ;
Pandit-Taskar, Neeta .
JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (10) :1697-1702
[8]   American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer [J].
Hammond, M. Elizabeth H. ;
Hayes, Daniel F. ;
Dowsett, Mitch ;
Allred, D. Craig ;
Hagerty, Karen L. ;
Badve, Sunil ;
Fitzgibbons, Patrick L. ;
Francis, Glenn ;
Goldstein, Neil S. ;
Hayes, Malcolm ;
Hicks, David G. ;
Lester, Susan ;
Love, Richard ;
Mangu, Pamela B. ;
McShane, Lisa ;
Miller, Keith ;
Osborne, C. Kent ;
Paik, Soonmyung ;
Perlmutter, Jane ;
Rhodes, Anthony ;
Sasano, Hironobu ;
Schwartz, Jared N. ;
Sweep, Fred C. G. ;
Taube, Sheila ;
Torlakovic, Emina Emilia ;
Valenstein, Paul ;
Viale, Giuseppe ;
Visscher, Daniel ;
Wheeler, Thomas ;
Williams, R. Bruce ;
Wittliff, James L. ;
Wolff, Antonio C. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) :2784-2795
[9]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21654, 10.3322/caac.21601]
[10]   TITRATION OF THE IN-VIVO UPTAKE OF 16-ALPHA-[F-18]FLUOROESTRADIOL BY TARGET TISSUES IN THE RAT - COMPETITION BY TAMOXIFEN, AND IMPLICATIONS FOR QUANTITATING ESTROGEN-RECEPTORS IN-VIVO AND THE USE OF ANIMAL-MODELS IN RECEPTOR-BINDING RADIOPHARMACEUTICAL DEVELOPMENT [J].
KATZENELLENBOGEN, JA ;
MATHIAS, CJ ;
VANBROCKLIN, HF ;
BRODACK, JW ;
WELCH, MJ .
NUCLEAR MEDICINE AND BIOLOGY, 1993, 20 (06) :735-745